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Abstract 
Small intestinal bleeding in Crohn’s disease patients with noncirrhotic portal hypertension 
and partial portal and superior mesenteric vein thrombosis is a life-threatening event. Here, a 
case is reported in which treatment with azathioprine may have resulted in nodular regenera-
tive hyperplasia, portal hypertension and portal vein thrombosis. The 56-year-old patient 
with Crohn’s disease developed nodular regenerative hyperplasia under treatment with aza-
thioprine. He was admitted with severe bleeding. Gastroscopy showed small esophageal 
varices without bleeding stigmata. Blood was detected in the terminal ileum. CT scan re-
vealed a partial portal vein thrombosis with extension to the superior mesenteric vein, thick-
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ening of the jejunal wall and splenomegaly. Because intestinal bleeding could not be con-
trolled by conservative treatment, the thrombus was aspirated and a transjugular intrahepatic 
portosystemic shunt (TIPS) was placed. Switching the immunosuppressive medication to 
infliximab controlled Crohn’s disease activity. Bleeding was stopped, hemoglobin normalized, 
and thrombocytopenia and bowel movements improved. In summary, small intestinal bleed-
ing in a Crohn’s patient with nodular regenerative hyperplasia, portal hypertension and por-
tal vein thrombosis can be efficiently treated by TIPS. TIPS placement together with inflixi-
mab treatment led to the improvement of the blood panel and remission in this patient. 
 © 2016 The Author(s) 
 Published by S. Karger AG, Basel 
Introduction 
Inflammatory bowel disease (IBD) often requires treatment with immunomodulatory 
agents, such as purines, or with biologicals, such as anti-TNF or anti α4β7 integrin antibodies 
[1]. The purine azathioprine can cause hepatitis, pancreatitis, bone marrow depression, nau-
sea and joint pain. Nodular regenerative hyperplasia (NRH) is observed in approximately 
1.25% of patients treated for 10 years with azathioprine [2, 3]. NRH can result in portal hy-
pertension with reduced portal flow leading to portosystemic shunts as esophageal varices, 
hypersplenism and thrombocytopenia [4]. 30–50% of patients with noncirrhotic portal hy-
pertension develop portal vein thrombosis [5, 6], which further aggravates portal hyperten-
sion. Life-threatening variceal bleedings are a serious complication of portal hypertension. 
Here, a patient with Crohn’s disease (CD) is reported who has likely developed azathio-
prine-induced NRH. A life-threatening small intestinal bleeding associated with portal hy-
pertension was successfully managed by transjugular intrahepatic portosystemic shunt 
(TIPS) placement. Infliximab has been introduced into the treatment of this patient to induce 
and maintain remission of CD. To our knowledge, this is the first reported CD case where a 
small intestinal bleeding with portal hypertension and partial thrombosis was successfully 
managed with TIPS placement and consecutive treatment with infliximab. Treatment with 
infliximab seems to be safe in this situation. 
Case Description 
A 54-year-old Caucasian male teacher had been admitted to the emergency unit with a 
circulation-relevant intestinal bleeding. The patient had a 19-year history of CD with stric-
turing behavior that required ileocecal resection. Five years before admission the patient 
had been treated with azathioprine. Two years after beginning treatment with azathioprine, 
leucocyte and thrombocyte numbers decreased. The patient was switched from azathioprine 
to methotrexate to control CD and arthralgia. Although azathioprine had been stopped and 
methotrexate introduced, cytopenia persisted and a bone marrow aspiration showed in-
creased megakaryopoiesis as sign of increased peripheral consumption (fig. 1a). A CT scan 
revealed signs of portal hypertension with splenomegaly and portosystemic shunts (fig. 1b). 
Esophagogastroduodenoscopy confirmed the presence of esophageal varices with cherry 
red spots (fig. 1c). Propranolol (80 mg/day) was introduced as primary bleeding prophylax-
is. Then, transjugular liver biopsy was performed. The hepatic venous pressure gradient 
between the liver veins and the wedged hepatic venous pressure was 7 mm Hg (normal 1–5 
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mm Hg) under therapy with propranolol. At that time, portal vein thrombosis was not pre-
sent. Liver histology revealed signs of a nodular regenerative hyperplasia (fig. 1d). 
At admission the patient reported that, without seeking medical advice, he had started a 
therapy with prednisone (150 mg/day) in addition to his treatment with methotrexate be-
cause he suffered from abdominal pain and increased frequency of bowel movements (diar-
rhea with loose stools up to 10 times per day). Physical examination showed slight tender-
ness of the left abdomen. Laboratory results revealed a platelet count of 44 g/l (normal value 
150–450 g/l). Within 2 h after admission, hemoglobin dropped from 121 to 100 g/l (normal 
value 140–170 g/l). Emergency gastroscopy showed small esophageal and fundal gastric 
varices without red signs or stigmata of recent hemorrhage (fig. 2a). Ileocolonoscopy 
demonstrated the presence of red blood in the neoterminal ileum, but the source of the 
bleeding could not be identified (fig. 2b). Likely, small intestinal bleeding was present in this 
patient. Consecutive CT angiography showed no active bleeding but demonstrated a partial 
thrombosis of the superior mesenterial and portal vein and a thickened proximal jejunal 
bowel wall (fig. 2c). Transfusion of 4 packs of 250 ml platelets increased the platelet count to 
77,000/μl. The somatostatin analog octreotide was given to lower portal pressure. However, 
intestinal bleeding persisted requiring the transfusion of 6 packs with 275 ml red cells. A CT 
abdominal angiography was repeated and again showed no active bleeding. 
Since intestinal bleeding persisted, partial thrombosis of the portal and superior mesen-
terial vein and clinical signs of portal hypertension with splenomegaly and portosystemic 
shunts were present, transhepatic pressure measurement, TIPS placement and thrombus 
aspiration were considered. After transjugular puncture of the portal vein, an Absolute Pro 
10 mm/60 mm 6F 8 stent was placed with the caudal end in the portal vein. Subsequently, a 
Fluency Vascular Stent Graft F9 and an additional Absolute Pro 10 mm/30mm 6F 8 stent 
were inlaid by stent-in-stent technique for proximal extension. After TIPS placement, the 
thrombus was aspirated. The pressure gradient measured directly in the portal vein and 
right atrium was successfully lowered from 19 to 6 mm Hg by the intervention. Intestinal 
bleeding stopped after TIPS placement and the patient could be discharged home. 
The patient was followed up in the outpatient clinic, where he reported episodes of ar-
thralgia and intermittent increased frequencies of bowel movements. Infliximab therapy was 
introduced, which led to an improvement of arthralgia and bowel movements. Regress of the 
esophageal varices was observed after TIPS placement. Hemoglobin normalized and throm-
bocytes counts doubled within 2 years (fig. 3). 
Discussion 
The presented case describes a patient with Cohn’s disease who developed NRH proba-
bly as consequence of the treatment with purines. As in our patient, risk factors for the de-
velopment of NRH in IBD patients are male sex, stricturing disease behavior and small bowel 
resection >50 cm [7]. Studies that searched for alternatives to azathioprine or 6-mer-
captopurine suggested that the purine 6-thioguanine has favorable short-term safety and 
efficacy [8]. However, approximately one third of patients treated with 6-thioguanine devel-
oped liver abnormalities as indicated by laboratory workup. More than two third of patients 
with abnormal liver chemistry had signs of NRH [9]. This indicates that the purine metabo-
lite 6-thioguanine is involved in the pathogenesis of NRH. 
Noncirrhotic portal hypertension and partial thrombosis of the superior mesenterial 
and portal vein resulted in a life-threatening small intestinal bleeding in this patient. IBD 
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patients have a two- to three-fold increased risk of suffering from thrombosis, and the ma-
jority of thrombotic events occur when active disease is present [10]. In the literature there 
are only few reports that describe the necessity of TIPS placement for the treatment of por-
tal hypertension in IBD patients. For example, one study described 9 patients with primary 
sclerosing cholangitis who underwent colectomy. The patients who received TIPS placement 
prior to colectomy had higher wound infection and dehiscence rates. Likely, this was more 
due to greater severity of cirrhosis and primary sclerosing cholangitis in this population 
[11]. Successful treatment of portal hypertensive stomapathy by TIPS placement has also 
been reported for both CD and ulcerative colitis [12, 13]. 
After release from the hospital, the patient reported about arthralgia and episodes of in-
creased bowel movements. CT scans demonstrated proximal jejunal bowel thickening. Like-
ly, activity of CD with involvement of jejunal segments was present. Together, this indicated 
that the patient was at an increased risk of suffering from thrombotic insults after release 
from the hospital. Since purines could not be given to this patient and methotrexate ineffi-
ciently controlled inflammation, therapy with biologicals was considered. A recent prospec-
tive study demonstrated that treatment with infliximab normalizes clot lysis profiles in CD 
[14]. Therapy with the anti-TNF antibody infliximab was hence started. Under this therapy 
hemoglobin normalized, thrombocytes almost doubled and arthralgia and bowel movement 
improved. 
Taken together, this case reports the successful treatment of small intestinal bleeding 
with TIPS in a CD patient with azathioprine-induced NRH. Treatment with infliximab in-
duced and maintained remission and seems to be well tolerated in this situation. 
Statement of Ethics 
This case report does not require approval by a local ethics committee. Informed con-
sent was obtained from the patient before publishing this case.  
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Fig. 1. Azathioprine induced NRH in a patient with CD. a CT scan with portosystemic shunts (arrow).  
b Endoscopic image of the esophagus with esophageal varices (asterisk) c Bone marrow aspirate with 
increased megakaryopoiesis (arrows; scale in micrometers on the top and bottom of the image). d Reticu-
lin stain of the liver showing atrophic and hypertrophic hepatocyte cords (arrows) as sign of NRH (scale in 
micrometers the top and bottom of the image). 
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Fig. 2. Admission to the emergency unit with a circulation-relevant intestinal bleeding. a Image of the duo-
denum during emergency esophagogastroduodenoscopy showing no blood. b Image of the terminal ileum 
with fresh blood. c CT scan at admission with partial thrombosis of the superior mesenterial and portal 
veins (arrows) and a thickened proximal jejunal bowel wall (asterisk). d–f TIPS placement and thrombus 
aspiration. Portosystemic pressure gradient between the right atrium und and the portal vein was lowered 
from 19 to 6 mm Hg after TIPS placement (portal vein: asterisk; TIPS: arrow; thrombus in the portal vein: 
arrowhead). HVPG = Hepatic venous pressure gradient. 
 
 
 
Fig. 3. Thrombocyte and hemoglobin levels. 
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